Bio-rad Laboratories Stock News

Laboratory Supplies Market: Overview The laboratory supplies market is estimated to gain tremendous growth prospects across the assessment period of 2020-2030. The growing demand for laboratory products on the back of the advancements in the chemical and biological research field will

Despite the COVID-19 pandemic induced challenges, rising demand for IVD coupled with dependence on AI & Robotics should lend support to the Zacks Medical-Products industry. ABT, BIO and HRC are well-p

Key Players Covered in the Point of Care Diagnostics Market Research Report Are F. Hoffmann-La Roche Ltd (Basel, Switzerland), Thermo Fisher Scientific Inc. (Massachusetts, U.S.), Abbott Laboratories (Illinois, U.S), Quest Diagnostics Incorporated (New Jersey, United States), BD (Franklin Lakes, U.S), bioMérieux SA (Marcy l''Etoile, France), Cardinal Health, Inc. (Ohio, U.S), Mesa Biotech (California, U.S), Cepheid (California, U.S), Trinity Biotech (Bray, Ireland), Quidel Corporation (San Diego, U.S.), Bio-Rad Laboratories Inc. (California, U.S) and other key market players Key Players Covered in the Point of Care Diagnostics Market Research Report Are F. Hoffmann-La Roche Ltd (Basel, Switzerland), Thermo Fisher Scientific Inc. (Massachusetts, U.S.), Abbott Laboratories (Illinois, U.S), Quest Diagnostics Incorporated (New Jersey, United States), BD (Franklin Lakes, U.S), bioMérieux SA (Marcy l''Etoile, France), Cardinal Health, Inc. (Ohio, U.S), Mesa Biotech (California, U.S), Cepheid (California, U.

Bio-Rad Laboratories (NYSE: BIO.B) is one of 42 publicly-traded companies in the Analytical instruments industry, but how does it contrast to its competitors? We will compare Bio-Rad Laboratories to similar companies based on the strength of its institutional ownership, profitability, risk, valuation, earnings, analyst recommendations and dividends. Analyst Recommendations This is a breakdown of current []

Robeco Institutional Asset Management B.V. increased its position in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 2.8% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 51,684 shares of the medical research companys stock after acquiring an additional 1,421 shares during the period. Robeco Institutional Asset Management B.V.s holdings in Bio-Rad Laboratories were worth $38,556,000 at []

The market report by Fact.MR envelopes an all-in information of the global Microplate Absorbance Reader market and the nature of the market growth over the foreseeable period. The report provides a comprehensive elaboration of the positives and negatives of the global

CENTRAL TRUST Co cut its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 5.0% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 660 shares of the medical research companys stock after selling 35 shares during the quarter. CENTRAL TRUST Cos holdings in Bio-Rad Laboratories []

Bio-Rad Laboratories (NYSE: BIO.B) is one of 42 public companies in the Analytical instruments industry, but how does it weigh in compared to its rivals? We will compare Bio-Rad Laboratories to similar companies based on the strength of its valuation, analyst recommendations, profitability, institutional ownership, risk, dividends and earnings. Earnings and Valuation This table compares []

"Helicobacter Pylori Diagnostics includes tests and mechanisms used to decide if one has an H.pylori infection. Tests include blood tests in which investigation of a blood sample can reveal evidence of an active or previous H. pylori infection in the

Bio-Rad Laboratories (NYSE: BIO.B) is one of 42 public companies in the Analytical instruments industry, but how does it weigh in compared to its peers? We will compare Bio-Rad Laboratories to similar companies based on the strength of its dividends, institutional ownership, profitability, analyst recommendations, earnings, valuation and risk. Earnings & Valuation This table compares []

Fundamentun LLC acquired a new stake in Bio-Rad Laboratories, Inc. (NYSE:BIO) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 332 shares of the medical research companys stock, valued at approximately $248,000. Other hedge funds have also recently bought and sold shares []

"Lateral Flow Assay Market, Drug Price, Sales and Clinical Trials Insight 2028 Report Highlights: Lateral Flow Assay Market Opportunity: > US$ 10.1 Billion by 2028 Lateral Flow Assay Market Growth: 100% Absolute Growth Till 2028 Lateral Flow Assay Market Size Opportunity by

Blood Bank Information System This Blood Bank Information System (BBIS) is connecting hospitals, UTD PMI, and personal donors within one web-based and mobile application. Web service, database service, and transaction-based service are the ideal applications for cloud computing. Ensures hospitals

Bio-Rad Laboratories, Inc. (NYSE:BIO.B)s share price hit a new 52-week high during mid-day trading on Monday . The company traded as high as $750.16 and last traded at $750.16, with a volume of 213 shares changing hands. The stock had previously closed at $769.89. The firm has a market cap of $22.44 billion, a price-to-earnings []